ArticleAdvances in therapy2025
Incidence and Prevalence of Chronic Spontaneous Urticaria Among Adult and Pediatric Populations in the United States.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.Clinical reviews in allergy & immunology · 2026Review
- A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib.Annals of medicine and surgery (2012) · 2026Article
- An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment.Allergy, asthma & immunology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPublished evidence on the epidemiology of chronic spontaneous urticaria (CSU) in the USA is limited. This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.
methodsThe target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan. The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart. The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017. In Optum EHR the incidence rate and prevalence were standardized by age and sex as compound strata and by age (adult and pediatric populations separately), and in both Optum CDM and MarketScan, data was standardized by sex as a single stratum of adult and pediatric populations. The age- and sex-standardized incidence rate and prevalence were calculated and reported per 100 person-years and per 100 persons (%), respectively.
resultsA total of 108,384 patients (adults, 72.1%; pediatric patients, 27.9%) from Optum EHR, 107,682 (adults, 78.5%; pediatric patients, 21.5%) from Optum CDM, and 278,311 (adults, 63.5%; pediatric patients, 36.5%) from MarketScan were identified with CSU diagnosis during the identification period. The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012-2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively. The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012-2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively. The sex-standardized combined (adult and pediatric) incidence rate and prevalence were 0.096 per 100 person-years and 0.283%, respectively. The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012-2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively. The sex-standardized combined (adult and pediatric) incidence rate and prevalence were 0.088 per 100 person-years and 0.244%, respectively.
conclusionThe findings of this study highlight a general increasing trend in the incidence and prevalence of diagnosed CSU over time among the US population. Comparatively, the incidence and prevalence were higher among pediatric patients than adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.